230 related articles for article (PubMed ID: 10692757)
1. Glycoprotein IIb/IIIa antagonists: do they have a role in the management of unstable angina?
Redwood S; Marber M; Jackson G
Int J Clin Pract; 1999 Dec; 53(8):618-22. PubMed ID: 10692757
[TBL] [Abstract][Full Text] [Related]
2. Tirofiban in acute coronary syndromes.
Menozzi A; Merlini PA; Ardissino D
Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):193-206. PubMed ID: 15853593
[TBL] [Abstract][Full Text] [Related]
3. [Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
Umman B
Anadolu Kardiyol Derg; 2006 Apr; 6 Suppl 1():13-9. PubMed ID: 16613770
[TBL] [Abstract][Full Text] [Related]
4. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.
Antman EM
Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302
[TBL] [Abstract][Full Text] [Related]
6. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
7. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
8. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes.
Elmouchi DA; Bates ER
Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb/IIIa inhibitors in unstable angina.
Theroux P
Curr Opin Cardiol; 1997 Sep; 12(5):447-52. PubMed ID: 9352171
[TBL] [Abstract][Full Text] [Related]
11. [Platelet activation and inhibition. Old and new platelet antiaggregants].
López Bescós L; Jiménez Nacher JJ
Rev Esp Cardiol; 1999; 52 Suppl 1():67-75. PubMed ID: 10364816
[TBL] [Abstract][Full Text] [Related]
12. Management of unstable angina and non-ST-segment elevation myocardial infarction.
Hanley HG; Nylk TM; Nguyen N
J La State Med Soc; 2001 Jun; 153(6):306-11. PubMed ID: 11480381
[TBL] [Abstract][Full Text] [Related]
13. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Quinn MJ; Moliterno DJ
Minerva Cardioangiol; 2002 Oct; 50(5):547-53. PubMed ID: 12384636
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
[TBL] [Abstract][Full Text] [Related]
17. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
19. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
Nguyen-Ho P; Levine GN
Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
Schriger DL; Herbert ME
Ann Emerg Med; 2001 Sep; 38(3):249-55. PubMed ID: 11524643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
